"We are very pleased to announce that patient enrollment is proceeding and treatment has begun in the Phase 1 trial of COTI-2. During preclinical studies, the activity of COTI‐2 in mutant-p53 ovarian cancer models was striking. In those studies, COTI-2 as a single agent either completely halted tumor growth or led to dramatic tumor regression depending on the dose amount and p53 mutation type. Moreover, there was no observable toxicity in those preclinical studies. We are eager to see similar results from this first-in-human study and anticipate that all three women in the first cohort will be receiving treatment by the end of February." - Dr. Wayne Danter
In June of 2014, COTI‐2 received the Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of ovarian cancer, one of the five main types of gynecological cancers.
Learn more about COTI-2 by visiting our website at http://criticaloutcome.com/coti-2.